Q-omics provides the consensus-scored GTF2A1L profile across patient tissues and cancer cell-line models. GTF2A1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GTF2A1L is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, GTF2A1L RNA expression shows 6,631 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where GTF2A1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2A1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2A1L survival associations across molecular data types. GTF2A1L RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2A1L RNA expression–survival associations across cancer types. High GTF2A1L expression shows unfavorable associations in UCEC, COAD and READ, but favorable associations in LIHC, KIRC and THCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UCEC as the clearest survival context for GTF2A1L RNA expression.
This table summarizes GTF2A1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2A1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2A1L shows lower tumor expression in KICH, KIRP, KIRC, BRCA, BLCA and UCEC. The KICH box plot shows higher GTF2A1L RNA expression in normal versus tumor tissue (log2 FC = −0.144, t-test p < 0.001).
This table shows molecular features associated with GTF2A1L in patient tissues and cancer cell lines. In patient samples, GTF2A1L shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2A1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OVARY.
